clinical trial · NCT06922110
An Open-Label Study of Azetukalner in Major Depressive Disorder
Major Depressive DisorderAzetukalner
brief summary
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).
started
Mar 18, 2025
primary completion
Jan 1, 2027
completion
Mar 1, 2027
last updated
Jun 1, 2026
official title
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol